# Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance-for-industry/a2b09b4f-527f-406f-a71d-c6e62d4737ad

> FDA guidance document: Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry. Issue date: February 16, 2018. Get complete insights and analysis.

---

## Details

- Title: Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-02-16
- Last Changed: 2020-04-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2015-D-1884">FDA-2015-D-1884</a>

## Related Documents

- [Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs](https://www.globalkeysolutions.net/guidances/guidance-document/atopic-dermatitis-timing-of-pediatric-studies-during-development-of-systemic-drugs/287c413c-cc5e-49ee-af83-9d7183bc4f4d)
- [Pediatric HIV Infection: Drug Development for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-hiv-infection-drug-development-for-treatment/2fd110e1-e45d-44ba-8efb-87a9ba7b8d23)
- [Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/amyotrophic-lateral-sclerosis-developing-drugs-for-treatment-guidance-for-industry-guidance-for-industry/933cd61f-72c5-470a-b6e9-21c7a3253529)